Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

PENG vs PHPB para Analgesia na Artroplastia da Anca

10 de novembro de 2026 atualizado por: Ankara City Hospital Bilkent

Eficácia Analgésica Pós-operatória do Bloqueio do Nervo Pericapsular (PENG) e do Bloqueio Pericapsular Posterior da Anca (PHPB) na Artroplastia da Anca

Total hip arthroplasty (THA) is a commonly performed surgical procedure, and its incidence continues to rise with the aging population. Effective postoperative analgesia facilitates early mobilization and accelerates recovery. The pericapsular nerve group (PENG) block provides analgesia to the anterior hip capsule by targeting the articular branches of the femoral, obturator, and accessory obturator nerves. However, due to the contribution of sacral plexus-derived nerves (quadratus femoris, superior gluteal, and inferior gluteal nerves) to posterior hip pain, anterior blocks alone may be insufficient.

This prospective study aims to compare the efficacy of preoperatively administered PENG block alone versus the combination of PENG and posterior hip pericapsular block (PHPB) in postoperative pain control after total hip arthroplasty. The primary outcome is postoperative pain intensity assessed by the Numerical Rating Scale (NRS). Secondary outcomes include the Quality of Recovery score (QoR-15), opioid consumption, manual muscle testing (MMT) results, time to mobilization, and block-related complications.

Visão geral do estudo

Descrição detalhada

Total hip arthroplasty (THA) is a widely performed surgical procedure, and its incidence continues to increase with the aging population. It is an effective intervention to improve the quality of life in patients with advanced osteoarthritis or rheumatoid arthritis. Postoperative pain is one of the most common complications following THA. Effective postoperative analgesia facilitates early mobilization and accelerates recovery. Early mobilization within the first 24 hours after surgery has been shown to significantly reduce the length of hospital stay.

Regional anesthesia techniques for postoperative analgesia in hip surgery play a crucial role in pain management and recovery. International pain management guidelines recommend multimodal analgesic protocols for elective total hip arthroplasty, emphasizing the role of peripheral nerve blocks as part of these strategies.

Current anatomical studies have demonstrated that the innervation of the hip joint capsule is derived from multiple nerves originating from the lumbosacral plexus. The density and distribution of this neural supply may vary among individuals depending on pelvic morphology, ethnicity, and sex. The anterior portion of the hip joint capsule is primarily innervated by articular branches of the femoral and obturator nerves, while the posterior aspect receives innervation from branches of the sciatic nerve, the superior gluteal nerve, and the nerve to quadratus femoris (NQF). The NQF, which provides significant sensory input to the posterior hip region, has become a key anatomical target for posterior hip-focused regional anesthesia techniques.

The pericapsular nerve group (PENG) block, first described by Girón-Arango et al., provides analgesia to the anterior hip capsule by blocking the articular branches of the femoral, obturator, and accessory obturator nerves. PENG block has been suggested to facilitate early mobilization and recovery compared to other anterior approaches. However, even with appropriate anterior blocks, posterior gluteal pain may persist in patients with hip pathology. This highlights the potential importance of targeting sacral plexus-derived nerves for comprehensive analgesia.

Recent research has shown that branches from the quadratus femoris nerve (NQF), superior gluteal nerve (SGN), and inferior gluteal nerve (IGN) contribute to the posterior capsule innervation of the hip joint. Regional anesthesia techniques targeting these posterior articular branches may enhance postoperative analgesia, promote early mobilization, and improve functional recovery. Consequently, the integration of sacral plexus-focused posterior blocks alongside anterior approaches is increasingly being emphasized in multimodal analgesia protocols for THA.

The combination of the posterior hip pericapsular block (PHPB) with the PENG block has been reported to provide balanced and effective analgesia across the entire hip capsule while preserving motor function.

The aim of this prospective study is to compare the efficacy of preoperatively administered PENG block alone versus the combination of PENG and posterior hip pericapsular block (PHPB) for postoperative pain control in patients undergoing total hip arthroplasty. The primary endpoint is postoperative pain intensity assessed using the Numerical Rating Scale (NRS). Secondary endpoints include the Quality of Recovery (QoR-15) score, opioid consumption, manual muscle testing (MMT) results, time to mobilization, and block-related complications.

Tipo de estudo

Observacional

Inscrição (Real)

127

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Çankaya
      • Ankara, Çankaya, Turquia (Türkiye), 06800
        • Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation, Ankara,Çankaya

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Adult patients aged 18 years and older, classified as ASA physical status I-II, scheduled for elective total hip arthroplasty under spinal anesthesia at Ankara Bilkent City Hospital. A total of 132 patients who meet the inclusion criteria and provide written informed consent will be enrolled in this single-center, prospective, randomized controlled trial.

Descrição

Inclusion Criteria:

  • Patients scheduled for elective total hip arthroplasty (THA) under spinal anesthesia
  • ASA physical status I-II
  • Age ≥18 years
  • Body Mass Index (BMI) between 18-35 kg/m²
  • Patients who provide written informed consent

Exclusion Criteria:

  • Age <18 years
  • ASA physical status ≥III
  • Known allergy or contraindication to study medications (local anesthetics, opioids, etc.)
  • Severe cardiac, renal, hepatic, or pulmonary failure
  • Revision total hip arthroplasty
  • Coagulopathy or anticoagulant use
  • Local infection or neuropathic findings at the injection site
  • Chronic inflammatory diseases or chronic corticosteroid use
  • Diagnosed neuropsychiatric disorders
  • Pregnancy or lactation
  • Inability or unwillingness to read, understand, or sign the informed consent form
  • Obesity (BMI >35 kg/m²)
  • Failed spinal anesthesia or conversion to general anesthesia
  • Active malignancy or patients receiving radiotherapy/chemotherapy
  • Active systemic infection or ongoing antibiotic therapy (except prophylaxis)
  • Contraindication to regional anesthesia techniques
  • Chronic opioid or analgesic use for pain disorders
  • History of intracranial mass, increased intracranial pressure, epilepsy, cerebrovascular accident, neuromuscular disease, or motor/sensory deficits

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_CONTROL
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
PENG Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule.

PENG + PHPB Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block and Posterior Hip Pericapsular Block (PHPB)

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule. In addition to the PENG block, a Posterior Hip Pericapsular Block (PHPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The local anesthetic will be injected between the piriformis muscle and the ischiofemoral ligament to target the posterior articular branches of the quadratus femoris, superior gluteal, and inferior gluteal nerves. The combined PENG + PHPB approach aims to provide comprehensive analgesia of both the anterior and posterior hip capsule while preserving motor function.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Postoperative pain
Prazo: Up to 48 hours postoperatively

Postoperative pain will be assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at rest and during movement at 0, 2, 6, 8, 12, 24, 36, and 48 hours after surgery. The NRS scores will be compared between the two study groups (PENG vs. PENG + PHPB) to evaluate the effectiveness of the blocks in postoperative analgesia following total hip arthroplasty.

Up to 48 hours postoperatively

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
QUALİTY OF RECOVERY-15
Prazo: Preoperative, 24, and 48 hours postoperatively

The quality of postoperative recovery will be assessed using the validated 15-item Quality of Recovery questionnaire (QoR-15). The total score ranges from 0 (very poor recovery) to 150 (excellent recovery). The score will be measured preoperatively and at 24 and 48 hours postoperatively to compare recovery quality between the two groups.

Preoperative, 24, and 48 hours postoperatively
MANUEL MUSCLE TEST
Prazo: 6, 12, and 24 hours postoperatively

Quadriceps muscle strength will be evaluated using the Manual Muscle Test (MMT) scale at 6, 12, and 24 hours after surgery. The MMT scale ranges from 0 (no contraction) to 5 (normal strength). A score <3 indicates quadriceps weakness.

6, 12, and 24 hours postoperatively
Rescue analgesic
Prazo: 0-48 hours postoperatively

The time from the end of surgery to the patient's first request for rescue analgesia will be recorded. Rescue analgesia consists of intravenous tramadol 100 mg administered if the Numeric Rating Scale (NRS) score is ≥ 4. This measure will compare the analgesic duration provided by the two blocks (PENG vs. PENG + PHPB).

0-48 hours postoperatively
Postoperative Nausea and Vomiting (PONV)
Prazo: 0-48 hours postoperatively

The presence of postoperative nausea and/or vomiting will be recorded during the first 48 hours following surgery.

0-48 hours postoperatively
Length of Hospital Stay
Prazo: Up to discharge (approximately 3-5 days postoperatively)

The duration of hospitalization will be measured from the day of surgery to discharge.

Up to discharge (approximately 3-5 days postoperatively)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Abdulkadir But, Professor, Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation,Ankara,Çankaya

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de dezembro de 2025

Conclusão Primária (Real)

15 de abril de 2026

Conclusão do estudo (Real)

1 de julho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

24 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de novembro de 2025

Primeira postagem (Real)

4 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de outubro de 2025

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • E2-25-12993

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever